Dimensional Fund Advisors LP Sells 412,889 Shares of CRISPR Therapeutics AG $CRSP

Dimensional Fund Advisors LP decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 45.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 494,218 shares of the company's stock after selling 412,889 shares during the quarter. Dimensional Fund Advisors LP owned 0.51% of CRISPR Therapeutics worth $23,488,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRSP. KBC Group NV raised its position in shares of CRISPR Therapeutics by 3,999.9% in the 1st quarter. KBC Group NV now owns 116,847 shares of the company's stock valued at $5,558,000 after acquiring an additional 113,997 shares during the period. Swiss National Bank raised its holdings in CRISPR Therapeutics by 5.1% during the 1st quarter. Swiss National Bank now owns 169,700 shares of the company's stock worth $8,073,000 after buying an additional 8,200 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in CRISPR Therapeutics by 11.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,932 shares of the company's stock valued at $290,000 after buying an additional 605 shares in the last quarter. Independent Financial Group LLC acquired a new position in shares of CRISPR Therapeutics in the first quarter valued at approximately $292,000. Finally, D.A. Davidson & CO. increased its position in shares of CRISPR Therapeutics by 5.9% during the first quarter. D.A. Davidson & CO. now owns 6,324 shares of the company's stock worth $301,000 after acquiring an additional 353 shares in the last quarter. Institutional investors own 69.20% of the company's stock.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, signaling continued confidence in CRISPR Therapeutics’ development pipeline and long-term commercial potential. Piper Sandler Reaffirms Their Buy Rating on CRISPR Therapeutics AG
• Positive Sentiment: Bullish commentary highlighted potential CASGEVY sales growth and expansion into in vivo gene editing through CTX310, which could broaden CRSP’s future revenue opportunities if clinical and commercial milestones are achieved. CRISPR Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to $1.30 per share from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. However, the firm still expects CRSP to remain unprofitable in 2026 and 2027.
• Negative Sentiment: Brookline reduced its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and lowered its FY2026 estimate to a loss of $5.63 from $5.36. Both forecasts are weaker than the broader current-year consensus loss estimate of $4.90, potentially weighing on sentiment.
• Negative Sentiment: The same analyst modestly cut projected profits for FY2028, FY2029 and FY2030, suggesting a slightly less optimistic view of CRSP’s long-term earnings ramp. Despite those reductions, the estimates still imply a transition from losses to profitability beginning in FY2028.

Insider Buying and Selling at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,786 shares of the company's stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider owned 19,357 shares in the company, valued at $1,076,636.34. This represents a 16.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

CRSP has been the subject of a number of research analyst reports. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the stock an "equal weight" rating in a research note on Thursday, June 11th. Evercore restated an "outperform" rating and issued a $76.00 price target on shares of CRISPR Therapeutics in a report on Monday, May 11th. Wall Street Zen cut CRISPR Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, July 5th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. Finally, Citigroup lifted their target price on CRISPR Therapeutics from $82.00 to $88.00 and gave the company a "buy" rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $68.06.

CRISPR Therapeutics Trading Down 1.5%

CRISPR Therapeutics stock opened at $51.64 on Friday. The company has a market cap of $4.99 billion, a price-to-earnings ratio of -10.85 and a beta of 1.74. The firm has a 50-day moving average of $52.42 and a 200-day moving average of $52.30. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.96. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $10.18 million during the quarter. On average, equities analysts expect that CRISPR Therapeutics AG will post -4.65 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source